When someone is diagnosed with ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS), one of the toughest questions is: What happens next? Not all in situ lesions progress to invasive cancer, yet many people feel pressure to treat aggressively for fear of missing something.
A new study from the American Association for Cancer Research suggests a promising—but still tentative—tool: a polygenic risk score (PRS), a number based on hundreds of inherited genetic variants. This approach may someday help personalize risk predictions for future breast events after an in situ diagnosis.
